Compare DOYU & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOYU | AVXL |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 115.9M |
| IPO Year | 2019 | 2013 |
| Metric | DOYU | AVXL |
|---|---|---|
| Price | $3.55 | $1.37 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.78 | N/A |
| AVG Volume (30 Days) | 28.8K | ★ 1.3M |
| Earning Date | 11-19-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.43 | $1.14 |
| 52 Week High | $7.23 | $8.97 |
| Indicator | DOYU | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 26.71 | 27.14 |
| Support Level | N/A | N/A |
| Resistance Level | $4.90 | $1.60 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 4.00 | 32.59 |
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company aims to build an integrated game-centric ecosystem of livestreaming, video, voice, graphic content, and other interactive and community features. The company operates the platform both on mobile apps and PC portals, through which users can enjoy immersive and interactive games and entertainment livestreaming, access a wide array of video and graphic content, and participate in community events and discussions.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.